Thermo Fisher Scientific Endostatin Monoclonal Antibody (1837-46)

Applications

Tested Dilution

Publications

Western Blot (WB)

1:50

View 1 publication 1 publication

Immunohistochemistry (IHC)

-

View 2 publications 2 publications

Immunohistochemistry (Paraffin) (IHC (P))

1:50

-

Immunohistochemistry (Frozen) (IHC (F))

1:50

-

Flow Cytometry (Flow)

1:50

-

ELISA (ELISA)

1:50

-

Product Specifications

Species Reactivity

Human

Published species

Bacteria, Human, Mouse

Host/Isotype

Mouse / IgG2b

Class

Monoclonal

Type

Antibody

Clone

1837-46

Immunogen

Recombinant human Endostatin

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.1 mg/mL

Purification

Protein G

Storage buffer

PBS with 0.1% BSA

Contains

0.02% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2081720

Product Specific Information

MA1-40230 detects Endostatin from human samples.

MA1-40230 has been successfully used in ELISA, flow cytometry, immunohistochemistry (frozen), immunohistochemistry (paraffin), and Western blot applications. For staining of paraffin sections antigen retrieval (microwave irradiation <2x7 minutes> in citrate buffer) is advised.

The MA1-40230 immunogen is human endostatin.

Target Information

Endostatin is able to avoke non-uniform response for proliferation, cell mount and migration of entothelial cells, which different endostatin binding characteristic, leads to the assumption that endostatin effect is strongly dependent from endothelial cell type. Furthermore endostatin inhibits angiogenesis and tumor growth in vivo by inducing apoptosis in endothelial cells. The local delivery of endostatin seems to specifically affect tumor-associated microvessels by reduction of the vessel density, diameter and functionality. Tumor cell migration and invasion was greatly reduced in the endostatin treated animals. Endostatin is non-toxic and does not induce aquired drug resistance and has therefor become a potent new therapy strategy in solid neoplasias. This therapy appears to have a high potential not only for the treatment of gliomas, the most common brain tumors, but also in other tumors. The ability of endostatin to inhibit neoangiogenesis is mediated, at least in part, by Zn^+2 binding and elastase processing. Widespread endostatin expression was found in elactic fibers in vessel walls and in some other basement membrane zones. Endostatin is released by neurons to accumulate in amyloid plaques in Alzheimer`s disease.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.